Mofecon-S 360 characteristics |
| Therapeutic classification | Selective immunosuppressant |
| Brand | Mofecon S-360 |
| Compounds | Mycophenolate Sodium |
| Dosage form | 360 mg |
| Dosage strength | tablet |
| Package | 30 tablet |
| Produced by | Concord Biotech / India |
| Indication | prevent organ rejection in patients who are at least three months of age who have received a liver transplant, a heart transplant, or a kidney transplant. |
| Administration | oral |
| Mechanism of action | Mycophenolate is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5′-monophosphate dehydrogenase. MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation. |
| Use in pregnancy and breastfeeding | D in pregnancy Information on the use of mycophenolate while breastfeeding is very limited. Be sure talk to your healthcare provider about all of your breastfeeding questions. |
| Precautions | The most common side effects of taking MOFECON S-360 TABLET are nausea, vomiting, diarrhea, stomach pain, headache, high blood pressure, and low number of white blood cells. |
| Drug interactions | other drugs that weaken the immune system/increase the risk of infection (such as natalizumab, rituximab). Mycophenolate may decrease the excretion rate of Abacavir, could result in a higher serum level. |
| Superior features | FDA approved BE study |
